GTC Biotherapeutics News

GTC Biotherapeutics Inc. has lined up $270,000 in "retention" payments for its senior executive team if the individuals stay with the struggling company beyond March 31.

GTC Biotherapeutics of Framingham said it will reduce its work force from 154 to 109 people as part of an effort to improve its financial position and meet Nasdaq compliance requirements.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. and a strategic shareholder in GTC, has exercised its option to purchase $12.8 million of additional convertible preferred stock under the terms described in the financing agreements approved by GTC shareholders in July 2009.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Struggling biotechnology developer GTC Biotherapeutics Inc. has appointed four new directors as part of a long-standing funding arrangement with LFB Biotechnologies , a France-based drug maker.

GTC Biotherapeutics, Inc. has appointed Evelyne Nguyen, Jean-Francois Prost M.D., Bertrand Merot, Ph.D., and William Heiden as directors.

GTC Biotherapeutics Inc. of Framingham has been warned by the Nasdaq stock market that the company's stock will be delisted for noncompliance with market value rules.

As a special thank you to their guests, El Fenix Mexican Restaurants will offer its famous "Wednesday Enchilad... MENLO PARK, Calif.-- --Unisfair, the leading provider of virtual events and business environments, announces the availability of its latest platform release.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

GTC Biotherapeutics, Inc.'s today announced that The Wall Street Journal has selected GTC as first runner-up in the "Medicine-Biotech" category of the Journal's 2009 Technology Innovation Awards.

GTC Biotherapeutics Inc. , a developer of drug therapies derived from animal proteins, saw its cash positioned whittled down to $4.7 million in the second quarter as a plummet in sales and a spike in research and development costs drenched its bottom line in red ink.

GTC Biotherapeutics Inc. lost $10.8 million during the second quarter, but said it had taken steps to "re-establish the financial stability" of the company.

GTC Biotherapeutics, Inc. announced today that its financial results for the second quarter 2009 will be released on Friday, July 31, 2009 followed by a webcast conference call starting at 10:00 a.m. Eastern Time.

Everyone knows you can make cheese from goats' milk. But believe it or not, now they're using the farm animals to make a life-saving drug.

Framingham-based GTC Biotherapeutics Inc. now has the rights to develop and commercialize a protein that could be used to treat multiple sclerosis and other autoimmune diseases.

GTC Biotherapeutics Inc. has licensed rights from Merrimack Pharmaceuticals Inc.

GTC Biotherapeutics Inc. , a developer of drug therapies derived from animal proteins, has acquired the rights to develop and sell a combination of potential auto-immune treatments discovered by Merrimack Pharmaceuticals Inc.

GTC Biotherapeutics, Inc. has obtained exclusive worldwide rights to the development and commercialization of recombinant human alpha-fetoprotein , including the recombinant, non-glycosylated version of rhAFP known as MM-093, for the treatment of autoimmune diseases from Merrimack Pharmaceuticals.

FRAMINGHAM, Mass.-- --GTC Biotherapeutics, Inc. has received a Staff Deficiency Letter from The NASDAQ Stock Market notifying GTC that for the 10 consecutive trading days the - 06/19/2009 - 04:08 PM AUSTIN, Texas-- --Mesa Royalty Trust announced the Trust income distribution for the month of June 2009.